{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:10:21Z","timestamp":1790187021434,"version":"4.1.0"},"reference-count":35,"publisher":"American Association for Cancer Research (AACR)","issue":"2","license":[{"start":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T00:00:00Z","timestamp":1677542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"HHS | NIH | National Cancer Institute","award":["P30CA006973"],"award-info":[{"award-number":["P30CA006973"]}]},{"name":"Believe Big Inc."},{"DOI":"10.13039\/501100004865","name":"Helixor Heilmittel","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004865","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,2,28]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Mistletoe extract (ME) is widely used for patients with cancer to support therapy and to improve quality of life (QoL). However, its use is controversial due to suboptimal trials and a lack of data supporting its intravenous administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>This phase I trial of intravenous mistletoe (Helixor M) aimed to determine the recommended phase II dosing and to evaluate safety. Patients with solid tumor progressing on at least one line of chemotherapy received escalating doses of Helixor M three times a week. Assessments were also made of tumor marker kinetics and QoL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Twenty-one patients were recruited. The median follow-up duration was 15.3 weeks. The MTD was 600 mg. Treatment-related adverse events (AE) occurred in 13 patients (61.9%), with the most common being fatigue (28.6%), nausea (9.5%), and chills (9.5%). Grade 3+ treatment-related AEs were noted in 3 patients (14.8%). Stable disease was observed in 5 patients who had one to six prior therapies. Reductions in baseline target lesions were observed in 3 patients who had two to six prior therapies. Objective responses were not observed. The disease control rate (percentage of complete\/partial response and stable disease) was 23.8%. The median stable disease was 15 weeks. Serum cancer antigen-125 or carcinoembryonic antigen showed a slower rate of increase at higher dose levels. The median QoL by Functional Assessment of Cancer Therapy-General increased from 79.7 at week 1 to 93 at week 4.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Intravenous mistletoe demonstrated manageable toxicities with disease control and improved QoL in a heavily pretreated solid tumor population. Future phase II trials are warranted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Although ME is widely used for cancers, its efficacy and safety are uncertain. This first phase I trial of intravenous mistletoe (Helixor M) aimed to determine phase II dosing and to evaluate safety. We recruited 21 patients with relapsed\/refractory metastatic solid tumor. Intravenous mistletoe (600 mg, 3\/week) demonstrated manageable toxicities (fatigue, nausea, and chills) with disease control and improved QoL. Future research can examine ME's effect on survival and chemotherapy tolerability.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-23-0002","type":"journal-article","created":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T10:15:24Z","timestamp":1675937724000},"page":"338-346","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Phase I Trial of Intravenous Mistletoe Extract in Advanced Cancer"],"prefix":"10.1158","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3658-1858","authenticated-orcid":true,"given":"Channing J.","family":"Paller","sequence":"first","affiliation":[{"name":"1The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2046-4366","authenticated-orcid":true,"given":"Lin","family":"Wang","sequence":"additional","affiliation":[{"name":"2Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0996-1137","authenticated-orcid":true,"given":"Wei","family":"Fu","sequence":"additional","affiliation":[{"name":"1The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2845-8115","authenticated-orcid":true,"given":"Rajendra","family":"Kumar","sequence":"additional","affiliation":[{"name":"1The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9097-9125","authenticated-orcid":true,"given":"Jennifer N.","family":"Durham","sequence":"additional","affiliation":[{"name":"1The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9613-3988","authenticated-orcid":true,"given":"Nilofer S.","family":"Azad","sequence":"additional","affiliation":[{"name":"1The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6646-0200","authenticated-orcid":true,"given":"Daniel A.","family":"Laheru","sequence":"additional","affiliation":[{"name":"1The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9914-6971","authenticated-orcid":true,"given":"Ilene","family":"Browner","sequence":"additional","affiliation":[{"name":"1The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6892-0140","authenticated-orcid":true,"given":"Sushant K.","family":"Kachhap","sequence":"additional","affiliation":[{"name":"1The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1731-7480","authenticated-orcid":true,"given":"Kavya","family":"Boyapati","sequence":"additional","affiliation":[{"name":"1The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1644-2378","authenticated-orcid":true,"given":"Thomas","family":"Odeny","sequence":"additional","affiliation":[{"name":"3Center for Cancer Research, NCI, NIH, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0852-803X","authenticated-orcid":true,"given":"Deborah K.","family":"Armstrong","sequence":"additional","affiliation":[{"name":"1The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3329-7106","authenticated-orcid":true,"given":"Christian F.","family":"Meyer","sequence":"additional","affiliation":[{"name":"1The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2174-3693","authenticated-orcid":true,"given":"Stephanie","family":"Gaillard","sequence":"additional","affiliation":[{"name":"1The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2443-8395","authenticated-orcid":true,"given":"Julie R.","family":"Brahmer","sequence":"additional","affiliation":[{"name":"1The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9020-8443","authenticated-orcid":true,"given":"Ivelisse","family":"Page","sequence":"additional","affiliation":[{"name":"4The Believe Big Institute of Health, Believe Big Inc., Cockeysville, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6489-6940","authenticated-orcid":true,"given":"Hao","family":"Wang","sequence":"additional","affiliation":[{"name":"1The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7079-8914","authenticated-orcid":true,"suffix":"Jr.","given":"Luis A.","family":"Diaz","sequence":"additional","affiliation":[{"name":"5Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2023,2,28]]},"reference":[{"key":"2023022814010342400_","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/1534735411423920","article-title":"How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis","volume":"11","author":"Horneber","year":"2012","journal-title":"Integr Cancer Ther"},{"key":"2023022814010342400_","doi-asserted-by":"crossref","first-page":"126","DOI":"10.7861\/clinmedicine.13-2-126","article-title":"Prevalence of use of complementary and alternative medicine (CAM) by patients\/consumers in the UK: systematic review of surveys","volume":"13","author":"Posadzki","year":"2013","journal-title":"Clin Med"},{"key":"2023022814010342400_","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1053\/sonc.2002.50006","article-title":"Mistletoe and cancer: controversies and perspectives","volume":"29","author":"Mansky","year":"2002","journal-title":"Semin Oncol"},{"key":"2023022814010342400_","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.3390\/molecules26123741","article-title":"Impact of harvest conditions and host tree species on chemical composition and antioxidant activity of extracts from viscum album L","volume":"26","author":"Pietrzak","year":"2021","journal-title":"Molecules"},{"key":"2023022814010342400_","first-page":"223","article-title":"Cytotoxic activity and absence of tumor growth stimulation of standardized mistletoe extracts in human tumor models in vitro","volume":"27","author":"Kelter","year":"2007","journal-title":"Anticancer Res"},{"key":"2023022814010342400_","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/1471-2407-8-161","article-title":"Induction of maturation and activation of human dendritic cells: a mechanism underlying the beneficial effect of Viscum album as complimentary therapy in cancer","volume":"8","author":"Elluru","year":"2008","journal-title":"BMC Cancer"},{"key":"2023022814010342400_","doi-asserted-by":"crossref","first-page":"13271","DOI":"10.1016\/S0021-9258(18)33441-0","article-title":"Action of viscumin, a toxic lectin from mistletoe, on cells in culture","volume":"257","author":"Stirpe","year":"1982","journal-title":"J Biol Chem"},{"key":"2023022814010342400_","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1006\/jmbi.1993.1682","article-title":"Crystallization of the ribosome inactivating protein ML1 from Viscum album (mistletoe) complexed with beta-D-galactose","volume":"234","author":"Sweeney","year":"1993","journal-title":"J Mol Biol"},{"key":"2023022814010342400_","first-page":"1521","article-title":"Differential effects of Viscum album extract IscadorQu on cell cycle progression and apoptosis in cancer cells","volume":"25","author":"Harmsma","year":"2004","journal-title":"Int J Oncol"},{"key":"2023022814010342400_","first-page":"1221","article-title":"In vitro effects of mistletoe extracts and mistletoe lectins. Cytotoxicity towards tumor cells due to the induction of programmed cell death (apoptosis)","volume":"43","author":"Janssen","year":"1993","journal-title":"Arzneimittelforschung"},{"key":"2023022814010342400_","first-page":"467","article-title":"Cytostatic and cytocidal effects of mistletoe (Viscum album L.) quercus extract Iscador","volume":"56","author":"Kovacs","year":"2006","journal-title":"Arzneimittelforschung"},{"key":"2023022814010342400_","first-page":"461","article-title":"Molecular mechanisms underlying the immunomodulatory effects of mistletoe (Viscum album L.) extracts Iscador","volume":"56","author":"Elluru","year":"2006","journal-title":"Arzneimittelforschung"},{"key":"2023022814010342400_","first-page":"295","article-title":"A plant lectin derived from Viscum album induces cytokine gene expression and protein production in cultures of human peripheral blood mononuclear cells","volume":"14","author":"Hostanska","year":"1995","journal-title":"Nat Immun"},{"key":"2023022814010342400_","first-page":"3322","article-title":"Increased secretion of tumor necrosis factors alpha, interleukin 1, and interleukin 6 by human mononuclear cells exposed to beta-galactoside-specific lectin from clinically applied mistletoe extract","volume":"50","author":"Hajto","year":"1990","journal-title":"Cancer Res"},{"key":"2023022814010342400_","doi-asserted-by":"crossref","first-page":"5893017","DOI":"10.1155\/2019\/5893017","article-title":"Mistletoe and immunomodulation: insights and implications for anticancer therapies","volume":"2019","author":"Oei","year":"2019","journal-title":"Evid Based Complement Alternat Med"},{"key":"2023022814010342400_","first-page":"2945","article-title":"Antiangiogenic properties of viscum album extracts are associated with endothelial cytotoxicity","volume":"29","author":"Elluru","year":"2009","journal-title":"Anticancer Res"},{"key":"2023022814010342400_","first-page":"CD003297","article-title":"Mistletoe therapy in oncology","volume":"2008","author":"Horneber","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"2023022814010342400_","doi-asserted-by":"crossref","first-page":"4628287","DOI":"10.1155\/2016\/4628287","article-title":"Intravenous mistletoe treatment in integrative cancer care: a qualitative study exploring the procedures, concepts, and observations of expert doctors","volume":"2016","author":"Kienle","year":"2016","journal-title":"Evid Based Complement Alternat Med"},{"key":"2023022814010342400_","volume-title":"Die Mistel in der Onkologie: Fakten und konzeptionelle Grundlagen","author":"Kienle","year":"2003"},{"key":"2023022814010342400_","doi-asserted-by":"crossref","first-page":"724258","DOI":"10.1155\/2014\/724258","article-title":"Adverse drug reactions and expected effects to therapy with subcutaneous mistletoe extracts (Viscum album L.) in cancer patients","volume":"2014","author":"Steele","year":"2014","journal-title":"Evid Based Complement Alternat Med"},{"key":"2023022814010342400_","doi-asserted-by":"crossref","first-page":"236310","DOI":"10.1155\/2014\/236310","article-title":"Safety of intravenous application of mistletoe (Viscum album L.) preparations in oncology: an observational study","volume":"2014","author":"Steele","year":"2014","journal-title":"Evid Based Complement Alternat Med"},{"key":"2023022814010342400_","first-page":"4451","article-title":"Intratumoral application of standardized mistletoe extracts down regulates tumor weight via decreased cell proliferation, increased apoptosis and necrosis in a murine model","volume":"26","author":"Beuth","year":"2006","journal-title":"Anticancer Res"},{"key":"2023022814010342400_","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1186\/s12906-017-1971-1","article-title":"Safety of intravenously applied mistletoe extract \u2013 results from a phase I dose escalation study in patients with advanced cancer","volume":"17","author":"Huber","year":"2017","journal-title":"BMC Complement Altern Med"},{"key":"2023022814010342400_","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1472-6882-11-116","article-title":"Safety and effects of two mistletoe preparations on production of interleukin-6 and other immune parameters \u2013 a placebo controlled clinical trial in healthy subjects","volume":"11","author":"Huber","year":"2011","journal-title":"BMC Complement Altern Med"},{"key":"2023022814010342400_","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/bjc.2016.172","article-title":"CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer","volume":"115","author":"Bronger","year":"2016","journal-title":"Br J Cancer"},{"key":"2023022814010342400_","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/(SICI)1096-9896(199912)189:4<552::AID-PATH469>3.0.CO;2-I","article-title":"Strong expression of the lymphoattractant C-X-C chemokine Mig is associated with heavy infiltration of T cells in human malignant melanoma","volume":"189","author":"Kunz","year":"1999","journal-title":"J Pathol"},{"key":"2023022814010342400_","doi-asserted-by":"crossref","first-page":"963","DOI":"10.21873\/anticanres.11405","article-title":"The role of IL-7 in immunity and cancer","volume":"37","author":"Lin","year":"2017","journal-title":"Anticancer Res"},{"key":"2023022814010342400_","doi-asserted-by":"crossref","first-page":"10267","DOI":"10.3390\/ijms160510267","article-title":"Mechanism of action of IL-7 and its potential applications and limitations in cancer immunotherapy","volume":"16","author":"Gao","year":"2015","journal-title":"Int J Mol Sci"},{"key":"2023022814010342400_","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3389\/fimmu.2013.00289","article-title":"Interleukin-18 and IL-18 binding protein","volume":"4","author":"Dinarello","year":"2013","journal-title":"Front Immunol"},{"key":"2023022814010342400_","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2023022814010342400_","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/s41591-020-0873-9","article-title":"IL-8 and cancer prognosis on immunotherapy","volume":"26","author":"Bakouny","year":"2020","journal-title":"Nat Med"},{"key":"2023022814010342400_","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00432-018-02837-4","article-title":"Mistletoe in oncological treatment: a systematic review: Part 1: survival and safety","volume":"145","author":"Freuding","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"2023022814010342400_","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s12906-020-03013-3","article-title":"Quality of life in cancer patients treated with mistletoe: a systematic review and meta-analysis","volume":"20","author":"Loef","year":"2020","journal-title":"BMC Complement Med Ther"},{"key":"2023022814010342400_","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1177\/1534735410369673","article-title":"Review article: influence of viscum album L (European mistletoe) extracts on quality of life in cancer patients: a systematic review of controlled clinical studies","volume":"9","author":"Kienle","year":"2010","journal-title":"Integr Cancer Ther"},{"key":"2023022814010342400_","doi-asserted-by":"crossref","first-page":"6405","DOI":"10.1007\/s00520-022-06921-x","article-title":"Cancer-related fatigue in patients treated with mistletoe extracts: a systematic review and meta-analysis","volume":"30","author":"Pelzer","year":"2022","journal-title":"Support Care Cancer"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-23-0002\/3268841\/crc-23-0002.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/3\/2\/338\/3277972\/crc-23-0002.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/3\/2\/338\/3277972\/crc-23-0002.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T15:11:20Z","timestamp":1679670680000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/3\/2\/338\/718406\/Phase-I-Trial-of-Intravenous-Mistletoe-Extract-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,28]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2,28]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-23-0002","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.22545981.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545987","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545975","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545993","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545981","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545975.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546005","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6551064.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545990.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545966.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545969.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545999","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545969","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545987.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545972.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545984.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546011","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546005.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545984","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546008","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546011.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545999.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545996","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546002","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546014","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545972","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546014.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545996.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545966","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545993.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6551064","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546008.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545990","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546002.v1","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,28]]}}}